Rbard, here are the details listed in every 10-Q
Post# of 148338
(Total Views: 627)
Posted On: 04/25/2020 9:33:44 PM
Rbard, here are the details listed in every 10-Q
Total 8.5% of net sales, 0.5 Million on filing BLA, 0.5 Million on Approval. See below from 10-Q. Vyera's deal for HIV in US is 50% gross profit margin, so after the 8.5% and 50 % for HIV only, that would be 41.5% to Cytodyn. We would get 91.5 % for COVID as it stands now unless some other deal is done.
Data from 10-Q
Licensing
Pursuant to the asset purchase with Progenics on October 16, 2012, the Company is required to pay Progenics the following ongoing milestone
payments and royalties: (i) $5.0 million at the time of the first U.S. new drug application approval by the FDA or other non-U.S. approval for the sale of
leronlimab (PRO 140); and (ii) royalty payments of up to five percent (5%) on net sales during the period beginning on the date of the first commercial sale
of leronlimab (PRO 140) until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years, in each case
determined on a country-by country basis. In addition, under a Development and License Agreement, dated April 30, 1999 (the “PDL License”), between
Protein Design Labs (now AbbVie Inc.) and Progenics, which was previously assigned to the Company, the Company is required to pay AbbVie Inc.
additional milestone payments and royalties as follows: (i) $0.5 million upon filing a BLA with the FDA or non-U.S. equivalent regulatory body; (ii)
$0.5 million upon FDA approval or approval by another non-U.S. equivalent regulatory body; and (iii) royalties of up to 3.5% of net sales for the longer of
10 years and the date of expiration of the last to expire licensed patent. Additionally, the PDL License provides for an annual maintenance fee of $150,000
until royalties paid exceed that amount. As of the date of this filing, while the Company has completed and filed the first of three portions of its BLA, the
Company currently expects to file the remaining two portions in the second
Total 8.5% of net sales, 0.5 Million on filing BLA, 0.5 Million on Approval. See below from 10-Q. Vyera's deal for HIV in US is 50% gross profit margin, so after the 8.5% and 50 % for HIV only, that would be 41.5% to Cytodyn. We would get 91.5 % for COVID as it stands now unless some other deal is done.
Data from 10-Q
Licensing
Pursuant to the asset purchase with Progenics on October 16, 2012, the Company is required to pay Progenics the following ongoing milestone
payments and royalties: (i) $5.0 million at the time of the first U.S. new drug application approval by the FDA or other non-U.S. approval for the sale of
leronlimab (PRO 140); and (ii) royalty payments of up to five percent (5%) on net sales during the period beginning on the date of the first commercial sale
of leronlimab (PRO 140) until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years, in each case
determined on a country-by country basis. In addition, under a Development and License Agreement, dated April 30, 1999 (the “PDL License”), between
Protein Design Labs (now AbbVie Inc.) and Progenics, which was previously assigned to the Company, the Company is required to pay AbbVie Inc.
additional milestone payments and royalties as follows: (i) $0.5 million upon filing a BLA with the FDA or non-U.S. equivalent regulatory body; (ii)
$0.5 million upon FDA approval or approval by another non-U.S. equivalent regulatory body; and (iii) royalties of up to 3.5% of net sales for the longer of
10 years and the date of expiration of the last to expire licensed patent. Additionally, the PDL License provides for an annual maintenance fee of $150,000
until royalties paid exceed that amount. As of the date of this filing, while the Company has completed and filed the first of three portions of its BLA, the
Company currently expects to file the remaining two portions in the second
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼